BeyondSpring Inc. (BYSI) stock
Close on Nov 11, 2026Market cap $26.47MP/E –Yield –
BeyondSpring Inc. reported revenue of $0 for the twelve months to Jun 30, 2026. Free cash flow was -$16.75M. At the latest close the market valued the company at $26.47M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $26.47M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -63.26%
Fundamentals
- Revenue
- $0
- Net income
- -$6.69M
- Free cash flow
- -$16.75M
- Book value per share
- -$0.86
- Diluted shares
- 41M
Trading
- Next earnings
- Nov 11, 2026 (estimated, before the open)
- Previous close
- $0.58
- Open
- $0.60
- Day's range
- $0.59 – $0.70
- Volume
- 78,300
- Average volume (20 days)
- 143,220
- Beta (5 years)
- 0.54
- 52-week range
- $0.42 – $2.44
- RSI (14 days)
- 51.9
- Volatility (1 year)
- 114.2%
- Relative volume
- 0.12×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BYSI | S&P 500 | Difference | BYSI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +6.3% | -2.4% | +8.7 pts | ||
| 3 months | -18.5% | -1.2% | −17.4 pts | ||
| Year to date | -60.5% | +12.3% | −72.8 pts | ||
| 1 year | -70.7% | +12.4% | −83.2 pts | ||
| 3 years | -31.5% | +78.8% | −110.3 pts | -11.9% | +21.4% |
| 5 years | -95.7% | +75.2% | −170.9 pts | -46.7% | +11.9% |
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BeyondSpring filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Results
- Update
- Results
- Results
- Results
About BeyondSpring
Pharmaceutical Preparations
BeyondSpring is a clinical-stage biopharmaceutical enterprise specializing in the research and advancement of novel cancer treatments for patients confronting serious unmet therapeutic needs. Its premier candidate, Plinabulin, operates as a selective immunomodulating microtubule-binding drug engineered to stimulate immune defenses and counter acquired resistance associated with immune checkpoint inhibitors across several malignancies, notably non-small cell lung cancer. In addition, the firm pursues pre-clinical small-molecule immune therapies and holds an ownership position in SEED Therapeutics, which creates targeted protein degradation drugs in conjunction with prominent pharmaceutical collaborators.
Company profile, executives and historyBeyondSpring stock: common questions
What is BeyondSpring's stock price?
BYSI closed at $0.64 on Nov 11, 2026, up 11.06% on the day. Over the past 52 weeks it traded between $0.42 and $2.44.
What is BeyondSpring's market cap?
BeyondSpring was worth $26.47M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
How much revenue does BeyondSpring make?
BeyondSpring reported revenue of $0 for the twelve months to Jun 30, 2026.
Does BeyondSpring pay a dividend?
No. BeyondSpring has not paid a cash dividend over the last twelve months.
When does BeyondSpring report earnings next?
BeyondSpring is expected to report Q3 FY2026 results on Nov 11, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has BYSI stock performed over the past year?
Including dividends, BYSI returned -70.7% over the past year, against +12.4% for the S&P 500.
How many BYSI shares are sold short?
2M shares were sold short at the latest FINRA report, 8.04% of the float, or 41.9 days of average trading volume.
Who are BeyondSpring's competitors?
Companies most similar to BeyondSpring by business, industry and size include APLM, NBP, CBIO, HCM, SLS.
See a number that looks wrong?